Jeanine L. Bussiere
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeanine L. Bussiere has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Antoinette MaassenVanDenBrink
Erasmus MC Rotterdam, PO Box 2040, 3000, CA, Rotterdam, the Netherlands
1 shared publicationBarbara J. Mounho
1 shared publicationCen Xu
Amgen Research, One Amgen Center Dr., Thousand Oaks, CA, 91320, USA
1 shared publicationCharles Dean
Amgen Research, One Amgen Center Dr., Thousand Oaks, CA, 91320, USA
1 shared publicationChristopher Horvath
From Amgen Inc, Thousand Oaks, California; Centocor Research & Development, Inc, Radnor, Pennsylvania; Genzyme, Framingham, Massachusetts; Genentech Inc, South San Francisco, California; and Taligen Therapeutics, Cambridge, Massachusetts
1 shared publicationCynthia Farman
1 shared publication
Latest Publications
- Open Access
- 1 August 2019
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 106, 224-238
Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine
- 1 August 2019
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 106, 224-238
Open AccessNonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine
- 1 December 2013
- Published by Elsevier in Reproductive Toxicology
- Vol. 42, 27-40
Reproductive toxicity of denosumab in cynomolgus monkeys
- 1 December 2013
- Published by Elsevier in Reproductive Toxicology
- Vol. 42, 27-40
Reproductive toxicity of denosumab in cynomolgus monkeys
- 1 August 2013
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 66 (3) , 269-278
Assessment of menstrual cycle length in cynomolgus monkeys as a female fertility endpoint of a biopharmaceutical in a 6month toxicity study
- 1 August 2013
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 66 (3) , 269-278
Assessment of menstrual cycle length in cynomolgus monkeys as a female fertility endpoint of a biopharmaceutical in a 6month toxicity study
- 1 April 2011
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 59 (3) , 493-502
Survey results on the use of the tissue cross-reactivity immunohistochemistry assay
- 1 April 2011
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 59 (3) , 493-502
Survey results on the use of the tissue cross-reactivity immunohistochemistry assay
- 1 May 2009
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 28 (3) , 230-253
Alternative Strategies for Toxicity Testing of Species-Specific Biopharmaceuticals
Although toxicology studies should always be conducted in pharmacologically relevant species, the specificity of many biopharmaceuticals can present challenges in identification of a relevant species. In certain cases, that is, when the clinical product is active only in humans or chimpanzees, or if the clinical candidate is active in other species but immunogenicity limits the ability to conduct a thorough safety assessment, alternative approaches to evaluating the safety of a biopharmaceutical must be considered. Alternative approaches, including animal models of disease, genetically modified mice, or use of surrogate molecules, may improve the predictive value of preclinical safety assessments of species-specific biopharmaceuticals, although many caveats associated with these models must be considered. Because of the many caveats that are discussed in this article, alternative approaches should only be used to evaluate safety when the clinical candidate cannot be readily tested in at least one relevant species to identify potential hazards.
- 1 May 2009
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 28 (3) , 230-253
Alternative Strategies for Toxicity Testing of Species-Specific Biopharmaceuticals
Although toxicology studies should always be conducted in pharmacologically relevant species, the specificity of many biopharmaceuticals can present challenges in identification of a relevant species. In certain cases, that is, when the clinical product is active only in humans or chimpanzees, or if the clinical candidate is active in other species but immunogenicity limits the ability to conduct a thorough safety assessment, alternative approaches to evaluating the safety of a biopharmaceutical must be considered. Alternative approaches, including animal models of disease, genetically modified mice, or use of surrogate molecules, may improve the predictive value of preclinical safety assessments of species-specific biopharmaceuticals, although many caveats associated with these models must be considered. Because of the many caveats that are discussed in this article, alternative approaches should only be used to evaluate safety when the clinical candidate cannot be readily tested in at least one relevant species to identify potential hazards.